Evaluation of the Pharmacokinetics and Safety of NT-814 in Post-Menopausal Women With Vasomotor Symptoms

Trial Profile

Evaluation of the Pharmacokinetics and Safety of NT-814 in Post-Menopausal Women With Vasomotor Symptoms

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs NT 814 (Primary)
  • Indications Hot flashes; Vasomotor symptoms
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms RELENT1
  • Sponsors NeRRe Therapeutics
  • Most Recent Events

    • 27 Jun 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.
    • 27 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 27 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top